Clinical Trial: Safety, Tolerability, and Immunogenicity of VAX-31 in Adults >=50 Years With Prior Pneumococcal Vaccination

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07425392) titled 'Safety, Tolerability, and Immunogenicity of VAX-31 in Adults >=50 Years With Prior Pneumococcal Vaccination' on Feb. 11.

Brief Summary: The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults >=50 years of age.

Study Start Date: Feb. 09

Study Type: INTERVENTIONAL

Condition: Pneumococcal Vaccines

Intervention: BIOLOGICAL: 31-valent pneumococcal conjugate vaccine

0.5 mL of VAX-31 will be administered into the deltoid muscle

BIOLOGICAL: PCV20

0.5 mL of the 20-valent pneumococcal conjugate vaccine will be administered into the deltoid muscle

Recruitment Status: RECRUITING

Sponsor: Vaxcyte, Inc...